Result of Meeting
Summary by AI BETAClose X
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
24 November 2025
Life Science REIT plc
(the "Company" or "LABS")
Result of General Meeting and Service of Protective Notice
On 4 November 2025, the Company announced the publication of a circular (the "Circular") to convene a general meeting to allow Shareholders to consider and, if thought fit, approve a change to the Company's investment objective and policy in order to implement the recommended proposals for managed wind-down of the Company.
The Board today announces that the ordinary resolution to adopt the New Investment Objective and Investment Policy of the Company has been approved by Shareholders.
Voting results of the General Meeting
The table below sets out the results of the vote at the General Meeting
|
|
Votes For (including discretionary) |
Votes Against |
Votes Total |
Votes Withheld¹ |
|
Number of Ordinary Shares |
167,215,462 |
920,924 |
168,136,386 |
191,130 |
|
% of voted Ordinary Shares |
99.45 |
0.55 |
100.00 |
- |
|
% of total voting rights2 |
47.78 |
0.26 |
48.04 |
- |
1 A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against the ordinary resolution
2 The number of Ordinary Shares in issue as at the voting record time of 6.30 p.m. (London time) on 20 November 2025 (the "Voting Record Time") was 350,000,000. As at that date no Ordinary Shares were held in treasury. Therefore, the total number of voting rights in the Company as at the Voting Record Time was 350,000,000.
Service of Protective Notice
The Board also announces that it served 2 years' protective notice to terminate the investment advisory agreement entered into between the Company, G10 Capital Limited and Ironstone Asset Management Limited, on the earliest date upon which protective notice could have been served.
Unless otherwise defined, all capitalised terms used in this announcement have the meanings given to them in the Circular.
The Company's LEI is 213800RG7JNX7K8F7525.
FOR FURTHER INFORMATION, PLEASE CONTACT:
|
Life Science REIT plc Claire Boyle, Chair
|
via Panmure Liberum |
|
MUFG Corporate Governance Limited - Company Secretary labs_cosec@cm.mpms.mufg.com
|
|
|
Panmure Liberum - Financial Adviser & Corporate Broker Tom Scrivens / Chris Clarke / Alex Collins / Ashwin Kohli
|
+44 20 7886 2500 |
|
G10 Capital Limited - AIFM Maria Baldwin
|
+44 20 7397 5450 |
|
FTI Consulting - PR Adviser Dido Laurimore / Richard Gotla / Oliver Parsons |
+44 20 3727 1000 |
The person responsible for arranging for the release of this announcement on behalf of the Company is MUFG Corporate Governance Limited.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 9 hours ago Luceco
- 10 hours ago Helios Towers
- 10 hours ago Wise Class A
- 10 hours ago EDX Medical Group Plc
- 10 hours ago Naked Wines